Monte Rosa Therapeutics (GLUE) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' Income towards Parent Company fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Income towards Parent Company is -$27.1 million, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Income towards Parent Company peaked at $46.9 million during Q1 2025, and registered a low of -$35.2 million during Q2 2023.
- For the 3-year period, Monte Rosa Therapeutics' Income towards Parent Company averaged around -$18.2 million, with its median value being -$30.3 million (2024).
- The largest annual percentage gain for Monte Rosa Therapeutics' Income towards Parent Company in the last 5 years was 24658.43% (2025), contrasted with its biggest fall of 1350.43% (2025).
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Income towards Parent Company stood at -$33.3 million in 2023, then surged by 140.32% to $13.4 million in 2024, then tumbled by 301.99% to -$27.1 million in 2025.
- Its last three reported values are -$27.1 million in Q3 2025, -$12.3 million for Q2 2025, and $46.9 million during Q1 2025.